OncoMatch/Clinical Trials/NCT07053072
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
Is NCT07053072 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Low Dose PD-1 mRNA LNP Vaccine and Medium dose PD-1 mRNA LNP vaccines for liver cancer.
Treatment: Low Dose PD-1 mRNA LNP Vaccine · Medium dose PD-1 mRNA LNP vaccines · High dose PD-1 mRNA LNP vaccines — Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — second-line
has failed second-line standard therapy
Cannot have received: mRNA drug
Patients who have been inoculated with mRNA drugs
Cannot have received: lipid nanoparticle drug
Participation in clinical trials involving lipid nanoparticles, a component of the study vaccine
Cannot have received: other investigational drug
Participation in a clinical trial of another drug within 4 weeks
Lab requirements
Blood counts
hemoglobin ≥80g/L (no blood transfusion within 14 days); neutrophil count >1.5×10^9 /L; platelet count ≥80×10^9 /L
Kidney function
endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula)
Liver function
total bilirubin ≤1.5 × ULN; ALT or AST ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN
Cardiac function
left ventricular ejection fraction (LVEF) ≥50%
Good function of major organs, i.e., relevant examination indexes within 14 days prior to randomization meet the following requirements: Routine blood tests: hemoglobin ≥80g/L (no blood transfusion within 14 days); neutrophil count >1.5×10^9 /L; platelet count ≥80×10^9 /L; Biochemical tests: total bilirubin ≤1.5 × ULN (upper limit of normal); blood alanine aminotransferase (ALT) or blood alanine transaminase (AST) ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN; endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula); cardiac Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify